Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

The haemoglobin glycation index as predictor of diabetes-related complications in the AleCardio trial.

van Steen SC, Schrieks IC, Hoekstra JB, Lincoff AM, Tardif JC, Mellbin LG, Rydén L, Grobbee DE, DeVries JH; AleCardio study group..

Eur J Prev Cardiol. 2017 Jan 1:2047487317692664. doi: 10.1177/2047487317692664. [Epub ahead of print]

PMID:
28186441
2.

Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial.

Lincoff AM, Tardif JC, Schwartz GG, Nicholls SJ, Rydén L, Neal B, Malmberg K, Wedel H, Buse JB, Henry RR, Weichert A, Cannata R, Svensson A, Volz D, Grobbee DE; AleCardio Investigators..

JAMA. 2014 Apr 16;311(15):1515-25. doi: 10.1001/jama.2014.3321.

PMID:
24682069
3.

Evaluation of the dual peroxisome proliferator-activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trial.

Lincoff AM, Tardif JC, Neal B, Nicholls SJ, Rydén L, Schwartz GG, Malmberg K, Buse JB, Henry RR, Wedel H, Weichert A, Cannata R, Grobbee DE.

Am Heart J. 2013 Sep;166(3):429-34. doi: 10.1016/j.ahj.2013.05.013.

PMID:
24016490
4.

PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.

Wilding JP.

Diabetes Obes Metab. 2012 Nov;14(11):973-82. doi: 10.1111/j.1463-1326.2012.01601.x. Review.

PMID:
22443197

Supplemental Content

Loading ...
Support Center